Arcturus Therapeutics Holdings Inc., of San Diego, reported preclinical data showing that Lunar-COV19 (ARCT-021) produced robust antibody responses, with neutralizing antibody titers increasing up to day 60, in mice. Single doses of the drug at both the 2-μg and 10-μg levels completely protected human ACE2 transgenic mice from both mortality and even measurable infection following wild-type SARS-CoV-2 challenge.

Bioaegis Therapeutics Inc., of Morristown, N.J., reported preclinical data showing recombinant human plasma gelsolin (rhu-pGSN) improves survival and reduces lung injury in a murine model of multidrug-resistant Pseudomonas aeruginosa pneumonia. Combining two sequential experiments, 31% of the mice receiving only meropenem survived for seven days compared with 75% survival when mice were given rhu-pGSN in addition to meropenem. The study was published in Open Forum Infectious Diseases.

Curevac NV, of Tubingen, Germany, said it received notification from the German Federal Ministry of Education and Research (BMBF) and expects to receive up to €252 million (US$298.3 million) to support the development of its COVID-19 vaccine candidate. In July, Curevac had applied for a grant as part of a special program to accelerate the research and development of vaccines against SARS-CoV-2. In addition to the further development of Curevac's vaccine candidate against COVID-19, the grant is expected to be used for the rapid expansion of the vaccine production. Payments are contingent on reaching predefined milestones. Curevac expects funding of up to €103 million in 2020 and up to €149 million in 2021.

Nanoviricides Inc., of Shelton, Conn., reported in an update that it is close to declaring a clinical candidate for treating patients infected with SARS-CoV-2. Previous work has shown antiviral therapies based on its nanomedicines platform to be effective against multiple coronaviruses in the company's own BSL2 Virology Lab, and therapies also have been shown to be highly effective in an animal study to combat infection by a related coronavirus that uses the same ACE2 receptor as does SARS-CoV-2. Nanoviricides said it has completed CMC studies and is in the process of drafting sections of an IND for a COVID-19 candidate.

Organovo Holdings Inc., of San Diego, said it regained compliance with the minimum bid price requirement for continued listing on Nasdaq.